Crystalline And Amorphous Forms Of A Beta-Arrestin Effector
AssigneeTrevena, Inc.
InventorsRitesh Sanghvi, Gregory Alcorn, Graham Richard Lawton, Meiki Yu, Matthew Ronsheim, Jiaher Tian, Shao Hong Zhou, Yuriy B. Kalyan
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel crystalline forms of a compound that acts as a β-arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a β-arrestin effector and uses thereof.
Claims21
1-42. (canceled)
A process for preparing a crystalline form of a peptide having a sequence of SEQ. ID. NO.1, comprising crystallizing SEQ. ID. NO. 1 to form a crystalline form of a peptide having a sequence of SEQ. ID. NO. 1.
A pharmaceutical composition comprising a crystalline form of a peptide having a sequence of SEQ. ID. NO.1.
A crystalline form of a peptide having a sequence of SEQ. ID. NO. 1.
Dependencies are inferred from the claim text.